Aclaris Therapeutics (ACRS) Gains from Sales and Divestitures (2014 - 2026)

Aclaris Therapeutics' Gains from Sales and Divestitures history runs 13 years deep, the most recent figure standing at $724606.0 for Q1 2026.

• In Q1 2026, Gains from Sales and Divestitures rose 37.82% year-over-year to $724606.0; the TTM figure through Mar 2026 stood at $724606.0 (up 37.82% YoY), while the FY2025 annual figure was $1.5 million, up 4.37% from the prior year.
• Gains from Sales and Divestitures was $724606.0 for Q1 2026 at Aclaris Therapeutics, down from $1.5 million in the prior quarter.
• In the past five years, Gains from Sales and Divestitures ranged from a high of $1.5 million in Q4 2025 to a low of $399716.0 in Q1 2024.
• Historically, Gains from Sales and Divestitures has averaged $681178.2 across 5 years, with a median of $542846.0 in 2024.
• The sharpest annual moves came in 2022 and 2024: Gains from Sales and Divestitures slumped 60.89% in 2022, then surged 97.69% in 2024.
• A 5-year view of Gains from Sales and Divestitures shows it stood at $533212.0 in 2022, then soared by 39.77% to $745279.0 in 2023, then soared by 97.69% to $1.5 million in 2024, then climbed by 4.37% to $1.5 million in 2025, then tumbled by 52.88% to $724606.0 in 2026.
• The last three Gains from Sales and Divestitures figures came in at $724606.0 (Q1 2026), $1.5 million (Q4 2025), and $608833.0 (Q3 2025), per Business Quant data.